In summary, recognizing the absence of definitive randomized data, available data suggest that the use of VET to treat troublesome genitourinary symptoms in women with a history of breast cancer, including women with ER positive disease, is likely to be safe. This evidence concerns the gene ESR1 and breast carcinoma.